<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Gaggl M</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The SARS-CoV-2 pandemic increased mortality and morbidity among immunocompromised populations. Vaccination is the most important preventive measure, however, its effectiveness among patients depending on maintenance immunoglobulin G (IgG) apheresis to control autoimmune disease activity is unknown. We aimed to examine the humoral immune response after mRNA-1273 Moderna&lt;sup>®&lt;/sup> vaccination in immunoapheresis patients.&lt;h4>Methods&lt;/h4>We prospectively monitored SARS-CoV-2 IgG spike (S) protein antibody levels before and after each IgG (&lt;i>exposure&lt;/i>) or lipid (LDL) apheresis (&lt;i>controls&lt;/i>) over 12 weeks and once after 24 weeks. Primary outcome was the difference of change of SARS-CoV-2 IgG S antibody levels from vaccination until week 12, secondary outcome was the </pubmed_abstract><journal>Frontiers in immunology</journal><pagination>969193</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9549982</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>SARS-CoV-2 IgG spike protein antibody response in mRNA-1273 Moderna&lt;sup>®&lt;/sup> vaccinated patients on maintenance immunoapheresis - a cohort study.</pubmed_title><pmcid>PMC9549982</pmcid><pubmed_authors>Strassl R</pubmed_authors><pubmed_authors>Gaggl M</pubmed_authors><pubmed_authors>Aigner C</pubmed_authors><pubmed_authors>Bond G</pubmed_authors><pubmed_authors>Schmidt A</pubmed_authors><pubmed_authors>Vychytil A</pubmed_authors><pubmed_authors>Wagner L</pubmed_authors><pubmed_authors>Aschauer C</pubmed_authors><pubmed_authors>Sunder-Plassmann G</pubmed_authors></additional><is_claimable>false</is_claimable><name>SARS-CoV-2 IgG spike protein antibody response in mRNA-1273 Moderna&lt;sup>®&lt;/sup> vaccinated patients on maintenance immunoapheresis - a cohort study.</name><description>&lt;h4>Background&lt;/h4>The SARS-CoV-2 pandemic increased mortality and morbidity among immunocompromised populations. Vaccination is the most important preventive measure, however, its effectiveness among patients depending on maintenance immunoglobulin G (IgG) apheresis to control autoimmune disease activity is unknown. We aimed to examine the humoral immune response after mRNA-1273 Moderna&lt;sup>®&lt;/sup> vaccination in immunoapheresis patients.&lt;h4>Methods&lt;/h4>We prospectively monitored SARS-CoV-2 IgG spike (S) protein antibody levels before and after each IgG (&lt;i>exposure&lt;/i>) or lipid (LDL) apheresis (&lt;i>controls&lt;/i>) over 12 weeks and once after 24 weeks. Primary outcome was the difference of change of SARS-CoV-2 IgG S antibody levels from vaccination until week 12, secondary outcome was the </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-04T21:41:08.115Z</modification><creation>2024-10-18T11:16:27.861Z</creation></dates><accession>S-EPMC9549982</accession><cross_references><pubmed>36225921</pubmed><doi>10.3389/fimmu.2022.969193</doi></cross_references></HashMap>